These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11796377)

  • 1. Azole cross-resistance in Aspergillus fumigatus.
    Mosquera J; Denning DW
    Antimicrob Agents Chemother; 2002 Feb; 46(2):556-7. PubMed ID: 11796377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and in vitro susceptibility to amphotericin B, itraconazole and posaconazole of voriconazole-resistant laboratory isolates of Aspergillus fumigatus.
    Manavathu EK; Abraham OC; Chandrasekar PH
    Clin Microbiol Infect; 2001 Mar; 7(3):130-7. PubMed ID: 11318811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the in-vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Rodríguez-Tudela JL; Mellado E; Martínez-Suárez JV; Monzón A
    J Antimicrob Chemother; 1998 Oct; 42(4):531-3. PubMed ID: 9818755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activities of amphotericin B, itraconazole and voriconazole against 150 clinical and environmental Aspergillus fumigatus isolates.
    Verweij PE; Mensink M; Rijs AJ; Donnelly JP; Meis JF; Denning DW
    J Antimicrob Chemother; 1998 Sep; 42(3):389-92. PubMed ID: 9786480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Correlations among itraconazole, voriconazole and posaconazole MICs in Aspergillus fumigatus].
    Guinea J; Peláez T; Alcalá L; Bouza E
    Enferm Infecc Microbiol Clin; 2007 May; 25(5):358-9. PubMed ID: 17504694
    [No Abstract]   [Full Text] [Related]  

  • 7. In vitro susceptibility of Aspergillus fumigatus to isavuconazole: correlation with itraconazole, voriconazole, and posaconazole.
    Gregson L; Goodwin J; Johnson A; McEntee L; Moore CB; Richardson M; Hope WW; Howard SJ
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5778-80. PubMed ID: 24041890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
    Verweij PE; Te Dorsthorst DT; Rijs AJ; De Vries-Hospers HG; Meis JF
    J Clin Microbiol; 2002 Jul; 40(7):2648-50. PubMed ID: 12089298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
    Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
    Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
    J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.
    Rodriguez-Tudela JL; Alcazar-Fuoli L; Mellado E; Alastruey-Izquierdo A; Monzon A; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2468-72. PubMed ID: 18474574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Activity of ASP2397 against Aspergillus Isolates with or without Acquired Azole Resistance Mechanisms.
    Arendrup MC; Jensen RH; Cuenca-Estrella M
    Antimicrob Agents Chemother; 2016 Jan; 60(1):532-6. PubMed ID: 26552973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.
    Ramani R; Gangwar M; Chaturvedi V
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3627-9. PubMed ID: 14576132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).
    Manavathu EK; Cutright JL; Loebenberg D; Chandrasekar PH
    J Antimicrob Chemother; 2000 Aug; 46(2):229-34. PubMed ID: 10933645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.
    Bueid A; Howard SJ; Moore CB; Richardson MD; Harrison E; Bowyer P; Denning DW
    J Antimicrob Chemother; 2010 Oct; 65(10):2116-8. PubMed ID: 20729241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Azole preexposure affects the Aspergillus fumigatus population in patients.
    Alanio A; Cabaret O; Sitterlé E; Costa JM; Brisse S; Cordonnier C; Bretagne S
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4948-50. PubMed ID: 22710122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods.
    Pfaller MA; Diekema DJ; Ghannoum MA; Rex JH; Alexander BD; Andes D; Brown SD; Chaturvedi V; Espinel-Ingroff A; Fowler CL; Johnson EM; Knapp CC; Motyl MR; Ostrosky-Zeichner L; Sheehan DJ; Walsh TJ;
    J Clin Microbiol; 2009 Oct; 47(10):3142-6. PubMed ID: 19692559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document).
    Espinel-Ingroff A; Diekema DJ; Fothergill A; Johnson E; Pelaez T; Pfaller MA; Rinaldi MG; Canton E; Turnidge J
    J Clin Microbiol; 2010 Sep; 48(9):3251-7. PubMed ID: 20592159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.